No Data
No Data
Needham Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating
TD Cowen Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $182
TD Cowen Reaffirms Their Buy Rating on Neurocrine (NBIX)
Neurocrine Biosciences Starts Commercial Sales of New Congenital Adrenal Hyperplasia Treatment
Needham Reiterates Hold on Neurocrine Biosciencesto Hold
Just Care Bears : I thought there’s a FDA approval going on on this today no news yet
Claudius NJIE Just Care Bears : yes good news is coming.
Claudius NJIE : pls run to at least 50